Assessing the charges associated with hematopoietic stem cell mobilization and remobilization in patients with lymphoma and multiple myeloma undergoing autologous hematopoietic peripheral blood stem cell transplantation

Transfusion

Volumn 51, Issue 6, 2011, Pages 1300-1313

  Hosing, Chitra ^a,b,c   Smith, Veronica ^a,b,c   Rhodes, Beverly ^a,b,c   Walters, Kent ^a,b,c   Thompson, Richmond ^a,b,c   Qazilbash, Muzaffar ^a,b,c   Khouri, Issa ^a,b,c   De Lima, Marcos ^a,b,c   Balzer, Richard J ^a,b,c   McMannis, John ^a,b,c   Champlin, Richard ^a,b,c   Giralt, Sergio ^a,b,c   Popat, Uday ^a,b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b GENZYME CORPORATION   (United States)

^c MEDITECH MEDIA LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; METHYLPREDNISOLONE; NAVELBINE; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; APHERESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DRUG DOSE ESCALATION; FEMALE; HEALTH CARE COST; HODGKIN DISEASE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; RESOURCE ALLOCATION; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IFOSFAMIDE; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 79958833404     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2011.03176.x     Document Type: Article

References (73)

1. Johnston A, Coiffier B,. HSCT for high-grade non-Hodgkin's lymphoma in adults. In:, Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, editors. The EBMT handbook: haematopoietic stem cell transplantation. Paris: European School of Haematology; 2008. p. 435-40.
2. Barosi G, Carella A, Lazzarino M, Marchetti M, Martelli M, Rambaldi A, Tarella C, Vitolo U, Zinzani PL, Tura S,; Italian Society of Hematology; Italian Society of Experimental Hematology; Italian Group for Bone Marrow Transplantation. Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2006; 91: 96-103. (Pubitemid 43235392)
3. Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, et al,.; National Comprehensive Cancer Network. National comprehensive cancer network: clinical practice guidelines in oncology: non-Hodgkin's lymphoma. J Natl Compr Canc Netw 2010; 8: 288-334.
4. American Society for Blood and Marrow Transplantation. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. [cited 2011 Apr 28]. Available from: URL
5. Sureda A,. Chapter 30: HSCT for Hodgkin's lymphoma in adults. In:, Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, editors. The EBMT handbook: haematopoietic stem cell transplantation. Paris: European School of Haematology; 2008. p. 455-61.
6. Hahn T, Wingard JR, Anderson KC, Bensinger WI, Berenson JR, Brozeit G, Carver JR, Kyle RA, McCarthy PL Jr,. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant 2003; 9: 4-37. (Pubitemid 41123051)
7. National Comprehensive Cancer Network. National comprehensive cancer network clinical practice guidelines in oncology: multiple myeloma. v2. 2009.
8. Perez-Simon JA, San Miguel J,. Chapter 26: HSCT for multiple myeloma in adults. In:, Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T, editors. The EBMT handbook: haematopoietic stem cell transplantation. Paris: European School of Haematology; 2008. p. 415-21.
9. Patriarca F, Petrucci MT, Bringhen S, Baldini L, Caravita T, Corradini P, Corso A, Di Raimondo F, Falcone A, Ferrara F, Morabito F, Musto P, Offidani M, Petrini M, Rizzi R, Semenzato G, Tosi P, Vacca A, Cavo M, Boccadoro M, Palumbo A,. Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts. Eur J Haematol 2009; 82: 93-105.
10. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ,; Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-83. (Pubitemid 36532313)
11. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R,. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-7. (Pubitemid 26240110)
12. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, Lauta VM, Bergonzi C, Barbui A, Caravita T, Capaldi A, Pregno P, Guglielmelli T, Grasso M, Callea V, Bertola A, Cavallo F, Falco P, Rus C, Massaia M, Mandelli F, Carella AM, Pogliani E, Liberati AM, Boccadoro M, et al,. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052-7. (Pubitemid 39507119)
13. Pettengell R, Morgenstern GR, Woll PJ, Chang J, Rowlands M, Young R, Radford JA, Scarffe JH, Testa NG, Crowther D,. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood 1993; 82: 3770-7. (Pubitemid 24006062)
14. Haas R, Mohle R, Frühauf S, Goldschmidt H, Witt B, Flentje M, Wannenmacher M, Hunstein W,. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-94. (Pubitemid 24175570)
15. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C, Clift R, Chauncey T, Klarnet J, Montgomery P, Petersdorf S, Weiden P, Witherspoon R, Buckner CD,. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-55.
16. Scott MA, Ager S, Jestice HK, Mahendra P, Marcus RE,. Failure to mobilise and harvest PBPC does not necessarily preclude the use of high-dose therapy and autologous stem cell rescue. Bone Marrow Transplant 1995; 15: 487-8.
17. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L, West W,. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-9.
18. Bender JG, To LB, Williams S, Schwartzberg LS,. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 329-41.
19. Schiller G, Vescio R, Freytes C, Spitzer G, Sahebi F, Lee M, Wu CH, Cao J, Lee JC, Hong CH, Lichtenstein A, Lill M, Hall J, Berenson R, Berenson J,. Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390-7.
20. Tricot G, Jagannath S, Vesole D, Nelson J, Tindle S, Miller L, Cheson B, Crowley J, Barlogie B,. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. Blood 1995; 85: 588-96.
21. Alegre A, Tomas JF, Martinez-Chamorro C, Gil-Fernández JJ, Fernández-Villalta MJ, Arranz R, Díaz MA, Granda A, Bernardo MR, Escudero A, Lõpez-Lorenzo JL, Fernández-Rañada JM,. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF versus G-CSF alone. Bone Marrow Transplant 1997; 20: 211-7. (Pubitemid 27361913)
22. Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yahalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD,. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3776-85.
23. Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C, O'Connor C, Berkman E, Erban JK, Sprague KA, Miller KB, Schenkein DP,. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059-64.
24. Damon L, Rugo H, Tolaney S, Navarro W, Martin T 3rd, Ries C, Case D, Ault K, Linker C,. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant 2006; 12: 316-24. (Pubitemid 43273717)
25. Gupta S, Zhou P, Hassoun H, Kewalramani T, Reich L, Costello S, Drake L, Klimek V, Dhodapkar M, Teruya-Feldstein J, Hedvat C, Kalakonda N, Fleisher M, Filippa D, Qin J, Nimer SD, Comenzo RL,. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. Bone Marrow Transplant 2005; 35: 441-7. (Pubitemid 40403345)
26. Bishton MJ, Lush RJ, Byrne JL, Russell NH, Shaw BE, Haynes AP,. Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol 2007; 136: 752-61.
27. Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Gastineau DA, Winters JL, Litzow MR,. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant 2009; 43: 619-25.
28. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691-7. (Pubitemid 26156299)
29. To LB, Shepperd KM, Haylock DN, Dyson PG, Charles P, Thorp DL, Dale BM, Dart GW, Roberts MM, Sage RE,. Single high doses of cyclophosphamide enable the collection of high numbers of hemopoietic stem cells from the peripheral blood. Exp Hematol 1990; 18: 442-7. (Pubitemid 20250496)
30. Bashey A, Donohue M, Liu L, Medina B, Corringham S, Ihasz A, Carrier E, Castro JE, Holman PR, Xu R, Law P, Ball ED, Lane TA,. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony- stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Transfusion 2007; 47: 2153-60. (Pubitemid 47623985)
31. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, Liso V,. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285-90. (Pubitemid 34229032)
32. 2 and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000; 82: 278-82. (Pubitemid 30045370)
33. Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, Munshi N, Singhal S, Mehta J, Tindle S, Nelson J, Bracy D, Mattox S, Tricot G,. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16: 1547-53. (Pubitemid 28175779)
34. Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Demuynck HM, Link H, Zander A, Barge A,. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-7.
35. Peters WP, Rosner G, Ross M, Vredenburgh J, Meisenberg B, Gilbert C, Kurtzberg J,. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-19. (Pubitemid 23101582)
36. Weisdorf D, Miller J, Verfaillie C, Burns L, Wagner J, Blazar B, Davies S, Miller W, Hannan P, Steinbuch M, Ramsay N, McGlave P,. Cytokine-primed bone marrow stem cells versus peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF versus G-CSF. Biol Blood Marrow Transplant 1997; 3: 217-23. (Pubitemid 127531541)
37. Putkonen M, Rauhala A, Pelliniemi TT, Remes K,. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies. Ann Hematol 2009; 88: 673-80.
38. Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A, Stepan DE, Somlo G, Margolin KA, Woo D, Niland JC, Forman SJ,. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994; 12: 2176-86.
39. Koc ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L, Fox RM, Szekely EM, Tainer N, Lazarus HM,. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18: 1824-30. (Pubitemid 30261919)
40. Fitoussi O, Perreau V, Boiron JM, Bouzigon E, Cony-Makhoul P, Pigneux A, Agape P, Nicolini F, Dazey B, Reiffers J, Salmi R, Marit G,. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837-42. (Pubitemid 32496417)
41. Jantunen E, Putkonen M, Nousiainen T, Pelliniemi TT, Mahlamaki E, Remes K,. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003; 31: 347-51. (Pubitemid 36410680)
42. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF,. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-56.
43. Dazzi C, Cariello A, Rosti G, Argnani M, Sebastiani L, Ferrari E, Zornetta L, Monti G, Nicoletti P, Baioni M, Salvucci M, Scarpi E, Marangolo M,. Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's lymphoma? Leuk Lymphoma 2000; 39: 301-10. (Pubitemid 32162367)
44. Bensinger W, DiPersio JF, McCarty JM,. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009; 43: 181-95.
45. Stiff P, Gingrich R, Luger S, Wyres MR, Brown RA, LeMaistre CF, Perry J, Schenkein DP, List A, Mason JR, Bensinger W, Wheeler C, Freter C, Parker WR, Emmanouilides C,. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 26: 471-81.
46. Dreger P, Klöss M, Petersen B, Haferlach T, Löffler H, Loeffler M, Schmitz N,. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970-8.
47. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G,. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-74. (Pubitemid 41208607)
48. Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD, Baker N, Barker P, Skacel T, Schmitz N,. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy. Haematologica 2008; 93: 405-12. (Pubitemid 351398642)
49. Glaspy JA,. Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Bone Marrow Transplant 1999; 23 Suppl 2: S21-7. (Pubitemid 29216707)
50. Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, Koreth J, Antin JH, Lee SJ,. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant 2008; 14: 197-207.
51. Svahn BM, Alvin O, Ringden O, Gardulf A, Remberger M,. Costs of allogeneic hematopoietic stem cell transplantation. Transplantation 2006; 82: 147-53. (Pubitemid 44126806)
52. Smith TJ, Hillner BE, Schmitz N, Linch DC, Dreger P, Goldstone AH, Boogaerts MA, Ferrant A, Link H, Zander A, Yanovich S, Kitchin R, Erder MH,. Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5-10. (Pubitemid 27020551)
53. Chabannon C, Le Corroller AG, Viret F, Eillen C, Faucher C, Moatti JP, Viens P, Vey N, Braud AC, Novakovitch G, Ladaique P, Stoppa AM, Camerlo J, Genre D, Maraninchi D, Blaise D,. Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation. Leukemia 2003; 17: 811-3. (Pubitemid 36519384)
54. Boeve S, Strupeck J, Creech S, Stiff PJ,. Analysis of remobilization success in patients undergoing autologous stem cell transplants who fail an initial mobilization: risk factors, cytokine use and cost. Bone Marrow Transplant 2004; 33: 997-1003. (Pubitemid 38744785)
55. Hartmann O, Le Corroller AG, Blaise D, Michon J, Philip I, Norol F, Janvier M, Pico JL, Baranzelli MC, Rubie H, Coze C, Pinna A, Méresse V, Benhamou E,. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126: 600-7. (Pubitemid 27172186)
56. Lee SJ, Klar N, Weeks JC, Antin JH,. Predicting costs of stem-cell transplantation. J Clin Oncol 2000; 18: 64-71. (Pubitemid 30036337)
57. Faucher C, le Corroller AG, Blaise D, Novakovitch G, Manonni P, Moatti JP, Maraninchi D,. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994; 14: 895-901.
58. Woronoff-Lemsi MC, Arveux P, Limat S, Deconinck E, Morel P, Cahn JY,. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients. Bone Marrow Transplant 1997; 20: 975-82. (Pubitemid 27510962)
59. Bredeson C, Malcolm J, Davis M, Bence-Bruckler I, Kearns B, Huebsch L,. Cost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC). Bone Marrow Transplant 1997; 20: 889-96. (Pubitemid 27493929)
60. Meisenberg B, Brehm T, Schmeckel A, Miller W, McMillan R,. A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells. Transfusion 1998; 38: 209-15. (Pubitemid 28145091)
61. Mishra V, Andresen S, Brinch L, Kvaløy S, Ernst P, Lønset MK, Tangen JM, Wikelund J, Flatum C, Baggerød E, Helle B, Vaaler S, Hagen TP,. Cost of autologous peripheral blood stem cell transplantation: the Norwegian experience from a multicenter cost study. Bone Marrow Transplant 2005; 35: 1149-53. (Pubitemid 40895170)
62. Mishra V, Vaaler S, Brinch L,. Cost analysis of autologous peripheral blood stem cell transplantation for multiple myeloma. Clin Lab Haematol 2003; 25: 179-84. (Pubitemid 36754227)
63. Meehan KR, Areman EM, Ericson SG, Matias C, Seifeldin R, Schulman K,. Mobilization, collection, and processing of autologous peripheral blood stem cells: development of a clinical process with associated costs. J Hematother Stem Cell Res 2000; 9: 767-71.
64. Gabriel IH, Sharon-Richman J, Olavarria E, Rahemtulla A, Kanfer E, Marin D, Milojkovic D, Rezvani K, MacDonald D, Szydlo R, Apperley J,. Efficacy, complication rates, and cost effectiveness of chemotherapy plus granulocyte colony stimulating factor conditioned mobilisation of peripheral blood haematopoietic stem cells in over 150 patients with haematological malignancies. Bone Marrow Transplant 2009; 43: S112.
65. Bennett CL, Armitage JL, Armitage GO, Vose JM, Bierman PJ, Armitage JO, Anderson JR,. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991. J Clin Oncol 1995; 13: 969-73.
66. Beard SM, Wall L, Gaffney L, Sampson F,. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy. Pharmacoeconomics 2004; 22: 207-24. (Pubitemid 38393391)
67. Sweetenham JW,. Economics of stem cell transplantation for lymphoma: counting the cost of living. Br J Cancer 2000; 82: 4-6. (Pubitemid 30008949)
68. Donato ML, Champlin RE, Van Besien KW, Korbling M, Cabanillas F, Anderlini P, Gajewski JG, Lauppe J, Durett A, Andersson B, Giralt S, Khouri I, Hagemeister F, Romaguera JE, Sarris A, McLaughlin P, Younes A, Ippoliti C, Blamble DA, Hester J, Gee A, Rodriguez MA,. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 1999; 35: 317-24.
69. Bargetzi MJ, Passweg J, Baertschi E, Schoenenberger A, Gwerder C, Tichelli A, Burger J, Mingrone W, Herrmann R, Gratwohl A, Wernli M,. Mobilization of peripheral blood progenitor cells with vinorelbine and granulocyte colony-stimulating factor in multiple myeloma patients is reliable and cost effective. Bone Marrow Transplant 2003; 31: 99-103. (Pubitemid 36240500)
70. Goterris R, Hernández-Boluda JC, Teruel A, Gõmez C, Lis MJ, Terol MJ, Tormo M, Solano C, Arbona C,. Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. Bone Marrow Transplant 2005; 36: 847-53. (Pubitemid 41655609)
71. Seshadri T, Al-Farsi K, Stakiw J, Ma C, Saragosa R, Franke N, Keating A, Crump M, Kuruvilla J,. G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation. Bone Marrow Transplant 2008; 42: 733-7.
72. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G,; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-73.
73. Dipersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Früehauf S, Horwitz M, Cooper D, Bridger G, Calandra G,; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-6.